Aridis Pharmaceuticals Inc. (ARDS) and Sutro Biopharma Inc. (NASDAQ:STRO) Comparison side by side

Both Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) and Sutro Biopharma Inc. (NASDAQ:STRO) are Biotechnology companies, competing one another. We will contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aridis Pharmaceuticals Inc. 2.76M 29.79 23.46M -2.98 0.00
Sutro Biopharma Inc. 38.42M 7.02 35.32M -2.21 0.00

Table 1 demonstrates Aridis Pharmaceuticals Inc. and Sutro Biopharma Inc.’s top-line revenue, earnings per share and valuation.


Table 2 shows Aridis Pharmaceuticals Inc. and Sutro Biopharma Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Aridis Pharmaceuticals Inc. -850.00% 54.6% -91.5%
Sutro Biopharma Inc. -91.93% 0% 0%


The Current Ratio and a Quick Ratio of Aridis Pharmaceuticals Inc. are 5 and 5. Competitively, Sutro Biopharma Inc. has 3.5 and 3.5 for Current and Quick Ratio. Aridis Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Sutro Biopharma Inc.

Insider & Institutional Ownership

Aridis Pharmaceuticals Inc. and Sutro Biopharma Inc. has shares owned by institutional investors as follows: 0.3% and 75.3%. Insiders owned 45.06% of Aridis Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 8.5% of Sutro Biopharma Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aridis Pharmaceuticals Inc. -1.12% 5.86% -28.74% -32.13% 0% -20.2%
Sutro Biopharma Inc. -9.77% -14.46% -12.05% 0% 0% 0.33%

For the past year Aridis Pharmaceuticals Inc. had bearish trend while Sutro Biopharma Inc. had bullish trend.


On 6 of the 10 factors Sutro Biopharma Inc. beats Aridis Pharmaceuticals Inc.

Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.

Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.